Search Press releases

18 Jan 2022

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Read More
8 Jan 2022

Disposals of own shares

Read More
3 Jan 2022

Disposals of own shares

Read More
21 Dec 2021

Disposals of own shares

Read More
16 Dec 2021

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial

Read More
10 Dec 2021

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More

Stay up-to-date on the latest news and information from UCB